Core Insights - Interpace Biosciences presented two scientific posters at the 2025 American Thyroid Association Annual Meeting, showcasing advancements in thyroid nodule testing and risk stratification [2][3][7] Group 1: Scientific Findings - The first poster demonstrated that 86% of previously insufficient thyroid FNA cases yielded successful molecular results using Interpace's ThyGeNEXT + ThyraMIRv2 testing from archival cytology slides, reducing the need for repeat FNAs [3][7] - The second poster reported on 28,144 indeterminate (Bethesda III/IV) nodules tested, revealing that ThyGeNEXT identified BRAF V600E-like alterations in approximately 4%-6% and RAS-like alterations in about 19%, with 76%-77% being mutation-negative [3][7] - ThyraMIRv2 microRNA profiling further refined malignancy risk, classifying over 90% of mutation-negative nodules as low risk, thus aiding clinical decision-making [3][4] Group 2: Clinical Implications - The integration of archival cytology slides in testing has shown practical advantages, enabling actionable molecular results and clearer patient care guidance [3][7] - The combination platform of ThyGeNEXT and ThyraMIRv2 supports more informed clinical decisions, particularly in managing RAS-like and mutation-negative indeterminate nodules [4][6] Group 3: Company Overview - Interpace Biosciences is positioned as an emerging leader in personalized medicine, offering specialized services from early diagnosis to targeted therapeutic applications [5][6] - The company provides clinically useful molecular diagnostic tests and bioinformatics services to evaluate cancer risk, leveraging advanced technology for improved patient management [6][8]

Core Viewpoint - Interpace Biosciences reported strong financial results for Q1 2025, highlighting record revenues in thyroid testing and a positive outlook for the full year despite the loss of PancraGEN revenue after May 2, 2025 [2][3]. Financial Performance - Q1 2025 net revenue was $11.5 million, a 13% increase from $10.2 million in Q1 2024 [6][7]. - Income from continuing operations was $1.8 million, up from $0.8 million in the prior year quarter, reflecting a $0.9 million improvement [2][7]. - Gross profit margin improved to 64% compared to 62% in the prior year quarter [7]. - Adjusted EBITDA for Q1 2025 was $2.1 million, compared to $1.2 million in Q1 2024 [7][21]. Revenue Growth - Cash collections reached $11.3 million, a 10% increase year-over-year, achieving record levels [6][7]. - Thyroid test revenue was $8.0 million, representing a 19% increase year-over-year, with test volume up 16% [6][7]. Future Guidance - The company initiated full-year 2025 revenue guidance of approximately $38 million, despite anticipated challenges from the loss of PancraGEN revenue [2][3]. Company Overview - Interpace Biosciences is focused on personalized medicine, providing molecular diagnostic tests and bioinformatics services to evaluate cancer risk [5].